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globally.T he World Is Flat (1), the bestselling book by Tom Friedman, described theemerging technological equity of developing nations relative to well-establishedindustrialized countries. In fact, he points out that the developing world has
some significant advantages in terms of manpower, costs, and regional organization. Re-
cent travels have made it clear to me that the same equity is occurring in the field of
cardiovascular medicine. This technological sophistication has many implications, one of
which is in regard to clinical research.
I have just returned from attending a conference in Russia celebrating the 15-year
anniversary of the Moscow City Center of Interventional Cardioangiology organized by
its Founding Director, Dr. David Iosseliani. A prominent component of the meeting
was live-case demonstrations of acute percutaneous interventions in ST-segment eleva-
tion myocardial infarction (STEMI) patients transmitted from the catheterization labo-
ratory by teleconference. During the meeting time on the first day of the conference
alone 4 STEMI patients were presented, discussed in detail, and underwent percutane-
ous intervention. Not only did the operators perform these procedures to existing stan-
dards, but in fact they had access to technology that is not available in the United
States. The discussions of the cases, carried out by luminary international interventional-
ists, attested to the expertise that existed in the Center. Lectures and participation on
panels demonstrated that similar cardiologic proficiency existed in other institutions in
Eastern Europe.
This experience in Moscow impressed me in several ways. To begin with, I was struck
by the number of acute STEMI patients that were filtered into this one center. I was
assured that this was not unusual, and in fact the second day started in the same fash-
ion. I am unaware of any hospital in the United States that currently treats such a large
number of acute infarction patients. Such patient numbers would clearly provide the op-
portunity for the expertise and the quality that typically follows high volume, and impart
the substrate for a robust clinical research effort. In addition, the cases were managed
just as they would have been in my own hospital, or in any of the leading institutions in
the United States, Western Europe, or Asia. It appears, therefore, that the management
of acute cardiovascular disease has been widely standardized.
The implications of my Russian experience were particularly impressive for clinical
research. Many essayists have written in regard to the “offshoring ”of clinical investiga-
tion, and I have discussed it in an earlier Editor’s Page (2). There is no question that an
increasing amount of clinical research has been and is being performed outside of the
United States, and in fact outside of traditional study sites in the industrialized world.
Large impactful trials, such as OAT and STICH, have drawn nearly 80% of patients
from other countries (3). The reasons for this are many and varied. The incremental
benefit of many therapies is now often modest enough that large sample sizes are re-
quired to determine benefit, and many study sites are necessary. The cost of research is
much less in developing countries, especially since enrollment is usually more rapid and
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environment outside the United States is frequently less
demanding. In addition, the inclusion of a diverse popula-
tion in a study may serve a social good and enhance ap-
plication of the results. Finally, inclusion of patients from
within a country may facilitate the approval and availabil-
ity of therapies in that country.
The “globalization” of clinical research has raised a
number of concerns. Patients in developing countries may
differ from those in industrialized nations in a number of
important ways. Genetic composition may vary, and envi-
ronmental conditions including diet, fitness, and comor-
bidities may be dissimilar. Access to physicians, medica-
tions, and medical procedures may be less, and the ability
to understand and make informed decisions regarding
participation in protocols may be lacking. Not surpris-
ingly, subgroup analysis of clinical trials has often demon-
strated differences in the response of North American
patients from those in the rest of the world (4). Examina-
tion of patient baseline characteristics and response to
therapy has now become somewhat routine for large clini-
cal trials.
My experience in Moscow has served to allay these
concerns a fair bit. It is clear that centers with contempo-
rary technology and expertise exist globally. Cardiovascu-
lar patients in these centers are managed in a standard
fashion according to existing guidelines by knowledgeable
and skilled physicians using up-to-date pharmaceuticals,
supplies, and equipment. At least in this respect, such
patients can be enrolled in clinical research with the ex-
pectation that the results observed can be extrapolated to
a general population.It goes without saying that all physicians, and indeed
all people, should be interested in global health. In this
regard, my recent trip to Russia was reassuring that state-
of-the-art care for cardiovascular disease is widely avail-
able. Moreover, the channeling of clinical volume, such as
into the Moscow City Center, provides an excellent op-
portunity for clinical investigation. As I sat in the meeting
room I marveled at the number of important clinical re-
search questions that could be relatively quickly answered at
such facilities. And given the standard of care, one could be
confident that medical practice would not invalidate the ex-
trapolation of the results to the rest of the world. This expe-
rience convinced me that the cardiovascular world has indeed
flattened, and that this will be of enormous benefit not only
for clinical care, but also for clinical investigation.
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